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paroxysmal kinesigenic dyskinesia in a Han
Chinese family
Zhisong Ji1†, Quanxi Su2†, Lingling Hu1, Qi Yang1, Cuixian Liu1, Jun Xiong1 and Fu Xiong1*Abstract
Background: Mutations in proline-rich transmembrane protein 2 (PRRT2) are a cause of paroxysmal kinesigenic
dyskinesia (PKD). In this study, we investigated the PRRT2 gene mutation in a Chinese Han family with PKD and
study the pathogenesis of the mutation with PRRT2 gene.
Methods: Peripheral venous blood was taken from the family members. Sanger sequencing was used for novel
mutation sequencing. For the pathogenesis with the novel mutation was analyzed by bioinformatics, real-time
PCR, subcellular localization and Western blot.
Results: The Sanger sequencing showed a novel mutation, c.186-187delGC, a deletion mutation, in exon 2 of the
PRRT2 gene, the frameshift mutation generated a truncated protein that was stably expressed in transfected Human
embryonic kidney (HEK) 293 cells. A subcellular localization assay in COS-7 cells with GFP-tagged protein showed
nuclear localization for the mutant protein while the wild-type protein was localized in membranes. Co-transfection
of HEK293 cells with wild-type and mutant expression plasmids cells did not influence mRNA or protein expression
from the wild-type plasmid.
Conclusions: Our findings demonstrated that the c.186-187delGC mutation resulted in a truncated protein from
the PRRT2 gene to involve in PKD pathogenesis with haploinsufficiency. The results extend the mutation spectrum
of the PRRT2 gene and provide a new example for studying the pathogenesis of the mutated PRRT2 gene.
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Paroxysmal kinesigenic dyskinesia (PKD) is a rare auto-
somal dominant neurological disorder with childhood or
early adulthood onset. PKD is characterized by recurrent,
brief attacks of involuntary movement that are usually
triggered by sudden voluntary movement [1-3]. Most idio-
pathic PKD patients have a family history of PKD, usually
inherited in an autosomal dominant pattern [4]. PKD
often improves with age and most patients show a favor-
able response to anticonvulsant medications, particularly
carbamazepine or phenytoin [4,5].
Proline-rich transmembrane protein 2 (PRRT2) is a
causative gene for PKDs [6,7]. We investigated a Han* Correspondence: xiongfu@smu.edu.cn
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unless otherwise stated.Chinese family with PKD and found the novel PRRT2
mutation c.186-187delGC that was heterozygous in the
family. We investigated the function and potential patho-
genic mechanism of the mutated gene. We found that the
novel mutation was a loss-of-function mutation in PRRT2
that caused PKD by haploinsufficiency. Our results could
be a reference model for studying the potential pathogenic
mechanism of PKD caused by variations in the PRRT2
gene.Methods
Patients
The study was approved by the Southern Medical
University ethics committee. Patients and relatives ana-
lyzed in the study gave signed informed consent before in-
clusion. Patients were recruited from outpatient clinics.
The proband (II-2), a 45-year-old woman, was referred tohis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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for consultation about involuntary movements. Clinical
examination of the proband was performed by an experi-
enced neurologist. Medical and neurologic histories were
obtained from 8 family members (Figure 1A). The 200
normal controls matched by gender and ethnic origin
were selected and recruited from healthy individuals from
the neurology clinics at Yunfu People’s Hospital.Mutation screening
A standardized phenol/chloroform extraction method was
performed to extract genomic DNA from peripheral
blood. Polymerase chain reaction (PCR) primers were de-
signed using Primer3 (http://frodo.wi.mit.edu/) to cover
the four PRRT2 exons. Appropriate annealing tempera-
tures were selected for PCR. PCR products were analyzed
with agarose gel electrophoresis and used for Sanger se-
quencing. This mutation that c.186-187delGC was not
detected in 200 healthy volunteers by high-resolution
melting analysis.Figure 1 Family pedigree and mutation screening. A. Family
pedigree. Arrow, proband; I-1, relative with the mutation who had a
similar attack with light symptoms several times in youth with recovery
without drugs; B. Mutation screening. Sequences of mutation (middle)
and wild-type (lower). Red (upper), amino acid differences between
mutation and wild-type.Bioinformatics
Three-dimensional structures of wild-type and mutant
PPRT2 proteins were predicted with I-TASSER, and
functional effects of the mutant protein were estimated
with SOSUI.
Cell localization studies
The subcellular localization of the PRRT2 protein and the
impact of the mutation was studied. COS-7 cells were
transfected with wild-type or mutant PRRT2 plasmids. At
48 hours after transfection, cells were rinsed three times
with PBS and nuclei were stained with 4′, 6-diamidino-2-
phenylindole (DAPI; Sigma, St. Louis, MO) and viewed by
fluorescence microscope (Nikon, Eclipse Ti-U, Tokyo,
Japan). The wild-type PRRT2 gene was cloned into the
HindIII and BamHI sites of pEGFP-C1 from GENEWIZ
(GENEWIZ, Inc. ,South Plainfield, New Jersey, USA) and
used as the backbone for cloning the mutant form of
PRRT2, ΔcPRRT2-pEGFP-C1. Mutant PRRT2 was cloned
by site-directed mutagenesis via QuikChange Site-Directed
Mutagenesis Kit (STRATAGENE). Point-mutation primers
were: primer-F, 5′- CCTGTGGACTCAGGCCAAGGCTG
GGCT-3′ and primer-R, 5′-CCAGCCCAGCCTTGGCCT
GAGTCCACAGGG-3′.
RNA analysis
Human embryonic kidney (HEK) 293 cells were cultured
in DMEM (Invitrogen) supplemented with 10% fetal bo-
vine serum. Recombinant plasmids with wild-type or
mutant PRRT2 genes were constructed and transfected
into HEK293 cells using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions. Total RNA
was isolated from transfected HEK293 cells. PrimeScript
RT-PCR kits (TaKaRa Biotechnology, Dalian, Co., Ltd)
were used to synthesize complementary DNA. SYBR
Green (Bio-Rad Laboratories, California, USA)-based
relative quantitative RT-PCR was used to measure
mRNA from wild-type and mutant PRRT2 alleles. Differ-
ences in mRNA levels between wild-type and mutant al-
leles was assessed by a two-standard-curves method.
Signal intensity from the PRRT2 gene was normalized to
the β-actin gene. The standard curve was the Ct value
plotted against the log of the input mRNA concentration
at five 10-fold serial dilutions. Three-step real-time PCR
analysis generated two standard curves for linear quanti-
tation of mRNA, with y = −3.169x + 15.08 (R2 = 0.999)
for PRRT2 mRNA and y = −3.182x + 13.7 (R2 = 0.996)
for β-actin mRNA. The primers of both wild-type and
mutant type: Forward (5′- > 3′): CCAGAAACCTCGG
GACTACA and Reverse (5′- > 3′): CTGTTCCGGGA
CATGACAG. Gene expression levels were calculated with
the (2–ΔΔCT) method in SYBR Green system. Target-gene
expression was normalized to β-actin expression. All real-
time RT-PCR reactions were performed in triplicate, and
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lating mean values and standard deviations. Dissociation
curve analysis was carried out after PCR amplification to
confirm the absence of non-specific amplification prod-
ucts and primer dimers. The result indicated that mRNA
expression level of mutant type was double of that in
wild-type.
PRRT2 protein in HEK293 cells
HEK 293 cells were transfected with pEGFP-C1 produ-
cing a ΔcPRRT2 fusion protein or wild-type PRRT2 to
measure protein expression from the wild-type or mu-
tant genes. Cells were harvested 24 h after transfection.
To study the influence of ΔcPRRT2 protein on the wild-
type PRRT2 protein, wild-type and mutant plasmids
were co-transfected into HEK293 cells with 2 μg of wild-
type plasmid and 2 μg, 1.5 μg, 1 μg or 0.5 μg mutant
plasmid. EGFP-C1 vector was used to balance the dose
to 0, 0.5 μg, 1 μg or 1.5 μg. Cells were homogenized in
RIPA buffer with Protease Inhibitor Cocktail (Sigma)
and blots were incubated with rabbit anti-GFP (1:1000,
Santa Cruz) overnight at 4°C, then goat anti-rabbit IgG-
HRP (1:5000, Santa Cruz) at room temperature for 1 hr,




The patient had a detailed clinical evaluation by an experi-
enced neurologist, including age and gender, age at onset,
attack frequency, duration of attack, triggers, affected
limbs and response to anticonvulsant. Clinical features of
the proband and her family members are in Table 1. The
proband (II-2) experienced onset at the age of 10 with
unilateral or bilateral paroxysmal choreiform movement
(with hunch), triggered by sudden activity such as
standing or walking, lasting less than one minute and
then alleviating. Initiation of attacks was once or twice a
month, gradually increasing in frequently to 4 to 5 times
a day. Valproic acid was ineffective, but carbamazepineTable 1 Clinical features and genotypes of the patient and fa






II-2 c.186-187delGC P63Qfs*70 45/F 10 4-5
I-1 c.186-187delGC P63Qfs*70 76/M No U
I-2 No No 68/F - -
II-1 NA NA 44/M - -
II-3 No No 41/M - -
II-4 NA NA 40/F - -
III-2 No No 13/M - -
III-1 No No 18/F - -
F: female; M: male; U: unknown; SM: sudden movement; NA: not available.decreased attacks. After the age of 18 years, attacks were
rare and the patient no longer took medicine. The pro-
band’s father (I-1), a 76-year-old man, had several simi-
lar attacks when he was younger, with lighter symptoms
and recovery without drugs. Other details of clinical
presentation were unclear.Identification of PRRT2 mutations
DNA sequencing revealed a deletion of two nucleotides
(GC) from codon 186 to codon 187 in the proband and
her father’s genomic DNA samples (Figure 1B). The dele-
tion created a stop codon (TGA) that resulted in prema-
ture termination of translation at codon 398 for a
truncated protein of 132 amino acids. Prediction using
SOSUI (http://www.bionity.com/en/encyclopedia/SOSUI/)
software indicated that the premature termination code led
to the loss of transmembrane function (Figure 2A) and
changed the tertiary structure and function of the PRRT2
protein.Functional analysis
Results showed that expression of the mutant was higher
than expression of the wild-type. We also found differ-
ences in the localization of wild-type and mutant pro-
tein. PRRT2 has 4 exons encoding 340 amino acids and
is predicted to have two transmembrane domains
(amino acids 269–289 and 318–338) [8]. The subcellular
localization of wild-type protein from pEGFP-C1-PRRT2
was assayed in COS-7 cells. The protein from ΔcPRRT2-
pEGFP-C1 was located in the nucleus. Thus, the trun-
cated protein had a different subcellular localization
(Figure 2B). An identically sized band (~90 kDa) was ob-
served from cells expressing the GFP-tagged wild-type
PRRT2 fusion protein. The GPF-tagged ΔcPRRT2 fusion
protein showed a band of ~45 kDa (Figure 2C). We did
not detect any obvious differences in the mRNA or pro-
tein when a wild-type PRRT2 plasmid was co-transfected
with different amounts of a plasmid expressing mutant





Triggers Affected limbs Response to
anticonvulsant
/d <1 min SM Right/left/bilateral Carbamazepine
U U U No
- - - -
- - - -
- - - -
- - - -
- - - -
- - - -
Figure 2 The function study with the mutated protein. A. Predicted protein structure: wild-type (upper) and mutant (lower) by I-TASSER.
B. COS7 cells with cellular location of wild-type and mutant. C. Wild-type and mutant protein by western blot. Left, HEK293 cells transfected with
GFP-tagged PRRT2 gave a ~90 kDa band; EGFP-fusion truncated mutant gave a ~45 kDa band. Right, HEK293 cells co-transfected with 2 μg
wild-type plasmid and 2 μg, 1.5 μg, 1 μg or 0.5 μg mutant plasmid showed no difference in wild-type PRRT2 protein. EGFP, 27 kDa; GAPDH
37 kDa. D. No significant difference was seen in protein expression for co-transfected wild-type and mutant plasmids at different ratios.
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PKD is a autosomal dominant hereditary disease with
clinical heterogeneity, such as the age of onset, which is
typically in childhood or adolescence; range, which is
4 months to 57 years; and clinical features of patients,
which varies among individuals, even in the same family
[3]. In this case, the proband harbored a novel mutation
from her father, however, her father had almost no clin-
ical symptoms. This example further demonstrated the
heterogeneity of the PKD phenotype. Other genetic fac-
tors such as pleiotropy might be further analyzed to elu-
cidate the heterogeneity.
PRRT2 has been widely investigated as a causative gene
of PKD and many mutations in the PRRT2 gene are asso-
ciated with PKD [9]. In the early literature, PRRT2 muta-
tions in PKD patients are in three general moleculargroups: a) single-base deletions, duplications or substitu-
tions leading to premature termination [10]; b) missense
mutations; and c) microdeletions leading to frameshifts.
We found a novel mutation (c.186-187delGC) that was a
deletion of two nucleotides, GC, in the coding region of
exon 2. The mutation caused a frameshift leading to a pre-
mature termination at codon 398. PRRT2 has 4 exons en-
coding 340 amino acids and the protein is predicted to
have two transmembrane domains of amino acids 269–
289 and 318–338 [8]. However, the truncated protein
lacked a proline-rich domain and two transmembrane do-
mains, which might have caused loss of protein function
and resulted in location of the protein in the nucleus [11].
Functional analysis of the truncated protein showed that
the mutation did not influence expression. Expression
with the wild-type protein indicated that the pathogenic
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think the overexpress of the mutation type will do nothing
on the wild type protein by an artificial assay. Based on
the experiments performed in vitro, we think that haploin-
sufficiency is not disputed. And nonsense mediated decay
is one of possible mechanism to haploinsufficiency [12],
the mechanism of this mutation needs further investiga-
tion. The cause for pathology was loss of function of the
mutation protein with the normal protein unable to sus-
tain normal functions, resulting in haploinsufficiency and
more research should be done to understand the mechan-
ism. PDK is a paroxysmal neurological disorder disease
with a favorable response to the ion-channel blocker
carbamazepine at a low dose. PKD is believed to be an ion
channelopathy [13]. As a transmembrane protein, PRRT2
might be involved in ion channels or regulation of ion
channels related to PKD [14]. The novel mutant protein
was located in the nucleus and might influence on the ion
channels loss of function.Conclusion
In conclusion, we found a novel mutation that resulted
in a truncated protein from the PRRT2 gene that was in-
volved in PKD pathogenesis. We performed functional
analysis of the novel mutation to elucidate the patho-
genic mechanism and haploinsufficiency. Our results ex-
tend the mutation spectrum of the PRRT2 gene of PKD.
With additional research, the potential mechanism asso-
ciated with this disease may be further understanding.
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